4 not yet recruiting, 2 recruiting. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Not yet recruiting 3 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Velzatinib: new trials by email Literature Review of Velzatinib trials Research Report on Velzatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 40 | 2026-11-10 | 2026-10-06 |
| A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 30 | 2026-10-23 | 2026-10-09 |
| A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants Velzatinib, Cyclosporine, Omeprazole - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 36 | 2026-10-16 | 2026-10-07 |
| A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) Velzatinib - Gastrointestinal Neoplasms | Phase 2 | Not yet recruiting | GlaxoSmithKline | 72 | 2026-10-13 | 2026-09-28 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib Velzatinib - Gastrointestinal Neoplasms | Phase 2 | Recruiting | GlaxoSmithKline | 24 | 2026-08-17 | 2026-10-01 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) Velzatinib, Imatinib - Gastrointestinal Stromal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 800 | 2026-07-27 | 2026-10-23 |
Gastrointestinal Neoplasms (5) · Gastrointestinal Stromal Tumors (3) · Renal Insufficiency (1)
GlaxoSmithKline (6)
Japan (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Finland (1) · France (1) · Greece (1) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · South Korea (1) · Spain (1)
2025 (1)